| |
Choosing the right partner to deliver decentralised clinical trials is crucial. ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities.
|
|
Today’s Big NewsOct 5, 2023 |
|
October 16-18, 2023 | Boston, MA This event is designed to bring together leaders and executives within the biotech and life sciences industry to discuss the most pressing challenges around product development, bringing an asset to market and building successful companies in this complex landscape. LAST CHANCE TO REGISTER!
|
|
| By Annalee Armstrong EQRx charged forward with a mission to develop a catalog of drugs at “radically lower prices." Now, in a regulatory filing, the behind-the-scenes unraveling has been revealed. |
|
|
|
By Max Bayer AbbVie is exercising its right to buy mitochondria-focused biotech Mitokinin for $110 million upfront. The acquisition gives AbbVie rights to a preclinical Parkinson's candidate. |
By James Waldron UniQure is losing a fifth of its employees—including its chief scientific officer—as well half of its R&D projects in a bid to claw back enough money to keep its planned gene therapy trials running into 2027. |
By Nick Paul Taylor Kyowa Kirin has addressed calls to strengthen its late-phase pipeline by inking a deal to buy Orchard Therapeutics for $387.4 million upfront. The takeover will give Kyowa control of a gene therapy that is on track to win approval in the U.S. in March. |
By James Waldron A month after Neurocrine Biosciences’ drug crinecerfont renewed analysts’ hopes of its blockbuster potential by acing a phase 3 study in adults with hyperplasia, the therapy has now scored another win in the pediatric version of the trial. |
By Nick Paul Taylor Innate Pharma’s lymphoma program has hit a safety snag, with the FDA imposing a partial clinical hold on studies after a patient died of a rare hematologic disorder. The biotech remains on course to report data from its two fully enrolled trials but saw its stock drop in the aftermath of the safety signal. |
By Gabrielle Masson Despite efforts to solve its credit woes, Impel Pharmaceuticals is still staring down the barrel of bankruptcy, launching a last-ditch attempt to save itself and search for strategic alternatives, including a potential sale. |
By Helen Floersh The findings are a positive signal for the companies' small molecule, which is in early-stage clinical trials for solid tumors. |
By Helen Floersh Fractyl Health’s GLP-1-based pancreatic gene therapy outperformed semaglutide injections for weight loss—at least in mice. |
By Fraiser Kansteiner Lonza has extended a long-term collaboration with an unnamed “major global biopharmaceutical partner” to crank up commercial supply of antibody-drug conjugates at its site in Visp, Switzerland. The deal is set to boost Lonza’s current bioconjugation capacity fourfold, thanks to the addition of two new bioconjugation suites. |
By Andrea Park Halfway through its fiscal year, Medtronic is finally filling the vacancy at the helm of its neuromodulation operating unit. |
By Heather Landi Research shows that the U.S. is facing a maternal health crisis. Diana Health partners with hospital and health system leadership to restructure their women’s health programs with a clinical redesign of labor and delivery. |
By Kevin Dunleavy After hearing a petition from Viatris, the U.S. Patent and Trademark Office will conduct a review to determine the validity of a patent held by Novo Nordisk. The review relates to semaglutide, the active ingredient in several of the company's diabetes and obesity superstars. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions. |
|
|---|
|
|
|
October 16-17 | Boston, MA LAST CHANCE! Enhance commercial success by optimizing the pipeline and making prioritization decisions. Don't miss this one of a kind event, Register today!
|
|
| WebinarEmbark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| |
|
